DHL Supply Chain 是美洲合同物流领域的，隶属于德国邮政 DHL 集团，正在进一步投资以加强其在北美的生命科学和医疗保健能力。该公司今天宣布，已承诺投资超过 7000 万美元用于开发额外的仓储基础设施并部署新技术以支持其制药和医疗设备客户。的承诺建立在 DHL Supply Chain 于 2019 年 6 月宣布的 1.5 亿美元投资的基础上，该投资旨在扩大其在美国的行业网络，并使关键医疗保健产品更贴近贸易伙伴和患者。
“由于我们在北美的行业地位以及我们在完全许可的站点上进行的投资，满足他们的存储和处理要求，DHL Supply Chain 近几个月已经做好了为我们的客户提供支持的有利条件。与此同时，我们认识到，随着市场对 Covid-19 大流行做出反应并适应解决患者日常医疗保健需求的新方法，需求只会在未来加剧，”生命科学和医疗保健总裁 Scott Cubbler 说。 DHL Supply Chain North America 的医疗保健。“通过进行这项投资，这也将使我们能够扩大提高效率的新技术的使用，我们为客户提供了一个进一步增长的平台，以及他们作为基本服务快速响应所需的灵活性-改变环境。”
DHL Supply Chain 目前在美国运营着 30 家设施，拥有超过 1100 万平方英尺的温控和认证基础设施。新投资将包括在田纳西州孟菲斯和印第安纳波利斯的新客户站点的开发以及新兴技术的部署，例如提高拣选生产率和站点吞吐量的 LocusBots 协作机器人。该公司今年早些时候宣布计划在今年年底前将其 LocusBots 车队增加到 1,000 台。
作为生命科学和医疗保健行业的物流供应商，DHL 通过一系列以患者为中心的整体解决方案提供具有前瞻性的智能医疗保健物流。超过 9,000 名专家在 DHL 的专用全球网络中工作，以便制药、医疗设备、临床试验和研究组织、批发商和商以及医院和医疗保健提供者在整个价值链中通过数字化连接起来，从临床试验到点关心，以及其间的每一步。
DHL Supply Chain, the Americas leader in contract logistics and part of Deutsche Post DHL Group, is making further investments to strengthen its life sciences and healthcare capabilities in North America. The company today announced that it has committed more than USD 70 million to develop additional specialized warehousing infrastructure and deploy new technologies in support of its pharmaceutical and medical devices customers. The latest commitment builds on the USD 150 million investment that DHL Supply Chain announced in June 2019 to expand its U.S. distribution network for the industry and bring critical healthcare products closer to trade partners and patients.
“DHL Supply Chain was already well-positioned to support our customers in recent months, thanks to our industry-leading footprint in North America and the investments we have made in fully licensed sites that meet their storage and handling requirements. At the same time, we recognize that demand will only intensify in the future as the market develops its response to the Covid-19 pandemic and adjusts to new ways of addressing patients’ everyday healthcare needs,” said Scott Cubbler, President of Life Sciences and Healthcare at DHL Supply Chain North America. “By making this investment, which will also allow us to expand the use of efficiency-boosting new technologies, we are providing our customers with a platform for further growth, as well as the flexibility they need to respond as essential services in a fast-changing environment.”
DHL Supply Chain currently operates 30 specialized facilities with over 11 million square feet of temperature-controlled and certified infrastructure in the United States. The new investment will include the development of new customer sites in Memphis, TN and Indianapolis, IN as well as the deployment of emerging technologies, such as the LocusBots collaborative robots that enhance picking productivity rates and site throughput. The company announced plans earlier this year to increase its fleet of LocusBots to 1,000 by the end of this year.
As the leading logistics provider for the life sciences and healthcare industry, DHL provides forward-thinking, intelligent healthcare logistics through a holistic range of patient-centric solutions. More than 9,000 specialists work across DHL’s dedicated global network so that pharmaceutical, medical devices, clinical trials and research organizations, wholesalers and distributors, as well as hospitals and healthcare providers are connected across the value chain and through digitalization, from clinical trials to point of care, and every step in between.
